NEW YORK (GenomeWeb News) – Orchid Cellmark said today that it will begin to consolidate its Nashville, Tenn., forensics testing operations into its Dallas, Texas, facility within the month.
The company expects to realize approximately $1.4 million in annual cost savings from operational efficiencies, reduction in lease and equipment expenses, and increased scalability following the consolidation.
According to a company spokesperson, approximately 25 staffers are located at the Nashville facility. All of them will be offered the opportunity to transfer to Dallas, and Orchid expects that a number of the workers will relocate. Overall it plans to add at least 20 new positions at the Dallas facility to support the increased workload.
Orchid President and CEO Thomas Bologna said in a statement that the consolidation of the company's Nashville operations into Dallas "will enhance our US-based forensics testing efficiencies and scalability, while bringing all of our forensics operations under one roof."
Bologna added that the company currently processes most of its forensic casework samples in Dallas, and that the larger facility in that city allows Orchid to add space and equipment to accommodate added business from Nashville.
"This consolidation makes sense for a number of strategic, financial, and pragmatic reasons, and represents the latest in our ongoing initiatives to provide high-quality DNA forensic testing services in an ever-increasing cost-effective structure," Bologna said.